Clinisphere PLS | Clinisphere PXC | Clinisphere PXA | Clinisphere PWC | Clinisphere PWA | |
---|---|---|---|---|---|
Base material | Porous, highly cross-linked, spherical PS-DVB, Particle Size: 50 μm, Pore Size: 80 Å, Specific Surface Area: 800 m2/g |
Porous, highly cross-linked, spherical PS-DVB, Particle Size: 50 μm, Pore Size: 80 Å Specific Surface Area: 800 m2/g |
Porous, highly cross-linked, spherical PS-DVB, Particle Size: 50 μm, Pore Size: 80 Å, Specific Surface Area: 800 m2/g |
Porous, highly cross-linked, spherical PS-DVB, Particle Size: 50 μm, Pore Size: 80 Å, Specific Surface Area: 800 m2/g |
Porous, highly cross-linked, spherical PS-DVB, Particle Size: 50 μm, Pore Size: 80 Å, Specific Surface Area: 800 m2/g |
Functional group | |||||
Retention mechanism | Non-polar and polar interactions | Non-polar interaction and cation exchange | Non-polar interaction and anion exchange | Non-polar interaction and weak cation exchange | Non-polar interaction and weak anion exchange |
Application | Pharmaceutical residues in animal tissue, such as tetracyclines, chloromycetin, sulfonamides, abamectin, macrolide antibiotics, nitrofurans, and pesticides in vegetables. | Basic compounds, such as sulfonamides and clenbuterol Biological samples, pharmaceuticals, and metabolites in plasma, serum, or urine | Compounds with groups as carboxyl and phenolic hydroxyl | Strong basic compounds, quaternary ammonium salts | For purification of strong acidic compounds |
More material with respect to application will available on request.